Intuitive Surgical is the market leader in robotic surgery, with a dominant 100% share in robotic procedures for abdominal soft tissue surgeries. The DaVinci system revolutionized surgical outcomes by offering superior dexterity, 3D visualization, and better surgeon ergonomics, leading to faster recovery times, fewer complications, and reduced hospital stays. Despite high upfront costs, robotic surgery demonstrates strong value when evaluated holistically—accounting for reduced readmissions, lower recurrence risks, and lower long-term care costs. Intuitive’s success stems from decades of innovation, regulatory compliance, and deep ecosystem integration with surgeons, hospitals, and academic institutions. The company has expanded beyond core urology and gynecology into new areas like the Ion system for lung biopsies, where it has achieved rapid growth. Revenue is driven by instruments (the largest component), robot sales, and services, with leasing and upgrade options reducing financial risk for hospitals. Digital tools now play a major role in pre-op planning, real-time guidance, and post-op analytics, enhancing surgical precision and training. While competition exists from legacy medical device firms and startups, Intuitive’s competitive position is reinforced by extensive clinical evidence, a loyal installed base, and a virtuous cycle of data collection and innovation. The business remains highly profitable, with strong margins and consistent cash flow, supported by a growing global footprint and increasing adoption in emerging markets.
[MUSIC PLAYING]
This is Business Breakdowns.
Business Breakdowns is a series of conversations
with investors and operators diving deep into a single business.
For each business, we explore its history, its business model,
its competitive advantages, and what makes it tick.
We believe every business has lessons and secrets
that investors and operators can learn from.
And we are here to bring them to you.
To find more episodes of Breakdowns,
check out joincollosses.com.
All opinions expressed by hosts and podcast guests
are solely their own opinions.
Hosts, podcast guests, their employers, or affiliates,
may maintain positions in the securities discussed
in this podcast.
This podcast is for informational purposes only
and should not be relied upon as a basis for investment
decisions.
This is Matt Russell.
And today, we are breaking down a giant
in the medical device space, Intuitive Surgical.
If you're looking for examples of how the world is a better
place today, look no further than surgical procedures.
Intuitive's DaVinci system is a pioneer in this area.
And it specifically reduces the invasiveness of surgery
and reduces the burden on surgeons themselves.
To break down Intuitive, I'm joined by Joe Thomas,
analyst at the Investment Manager, 91.
Joe walks us through the history of surgical procedures,
and it's quite a history, depending on how far
you want to go back.
The emergence of robotics and surgery
and how intuitive has emerged as the winner in the space.
Please enjoy this breakdown on Intuitive Surgical.
[MUSIC PLAYING]
OK, Joe, excited to break down Intuitive Surgical today
at the time that we are recording $140 billion
market cap business, sitting at all time highs, actually,
at this moment in time.
But until you sent it across via email,
it wasn't a name that I knew of, certainly wasn't familiar with.
So I thought maybe we could just start
with a simple introduction to intuitive surgical
and how you would describe them to those
that aren't familiar with the business.
Intuitive Surgical make robots.
These robots are called DaVinci systems,
and they use to perform surgical procedures.
Specifically, they're used to do surgery in a minimally
invasive way, and they use mostly for procedures
in the abdomen.
Intuitive also make surgical instruments
and those are used alongside these robots.
They're the dominant player in robotic surgery
with essentially 100% market share for this type of surgery.
I can imagine that this portion of the market
has been growing, and I want to touch on the history shortly.
But can you just give us a sense of how big of a market
robotic surgery is today?
Sizing the total surgical market is tricky,
and it relies on amalgamating quite a few different sources.
There's somewhere in the order of two to 300 million
total procedures, broadly, performed annually worldwide.
Almost 10% of that is soft tissue surgery,
and that's what's relevant for intuitive surgical.
Within those, about 7 million procedures
are currently in the addressable market.
Those are procedures where robotic surgery has approvals,
and it makes sense economically to use robotics.
If we zoom down to where robotics are currently being used,
that's just over 2 million procedures
done on DaVinci systems in 2023.
And can you bring us back in time?
I can imagine 100 years ago, 200 years ago,
there was surgery being done sometimes without any type
of anesthetics, sometimes without very clean tools.
So wherever you want to start, in terms of the evolution
of the surgical market, I'll leave that up to you.
But it would be good to just get some history,
particularly as robotic surgical operations
started coming into play as well.
So if you go back really far, 5,000 years,
you've got procedures like treponing
of the oldest known surgeries I put that in inverted commas.
And amazingly, you see some evidence of healings.
Some patients survive the procedure
of having a whole drilled in their skull.
And then you had other procedures performed
in ancient Greece, setting broken bones and things.
By the 10th century, you got some evidence
and writing to orthopedics and ENT.
But essentially before the 19th century,
as you've alluded to, the introduction of anesthetics
and antiseptics, surgery was a horrifying prospect
for patients, a high likelihood of infection and death,
not to mention the patient was conscious during the operation.
So they really knew what was going on.
If you read some of the contemporaneous accounts
of 19th century surgery, it's really something else.
And this meant that surgery is mostly
limited to what you'd call external procedures.
So that's amputations and treating wounds.
And then if you fast forward to the 20th century,
this is when people began more widely accepting germ theory.
And you had more antiseptic measures.
And this enabled the more modern era of surgery.
So that included the ability to perform longer,
more complicated internal procedures.
And internal procedures on organs in the abdomen
is where we'll focus as this is intuitive score area.
So if you think about those procedures
in the abdomen, soft tissue surgery,
there are two broad camps there.
You've got open surgery or minimally invasive.
Now open involves quite a large incision in the patient.
So the surgeon has got access to the full surgical site
by its access to the area in question and great visibility.
The drawbacks are that the patient
has a painful recovery.
They've got a long healing process,
not just from the internal procedure,
but from the big incision in their abdomen.
And this is accompanied with a high risk of infection,
larger scars, disfigurement, and so forth.
Minimally invasive surgery involves making a small incision
or multiple incisions in some parts of the abdomen.
And the surgeon puts an endoscope through this keyhole incision,
some people will be familiar with the keyhole terminology.
So they put an endoscope into see what's going on
as well as the instruments that they're going to use
to carry out the procedure.
And this solves a lot of the drawbacks of open surgery.
The patient recoveries faster,
the chance of infection is lower.
And this technique is known as laparoscopic surgery
or lap surgery for short.
The first procedure like this was done in 1910
and there was quite a bit of development
through the 1950s, 60s, and 70s especially.
But it wasn't until the early 80s
that it started being documented.
And then in the 1990s lap techniques
were seeing rapid adoption.
Because this is what patients preferred,
this is what surgeons preferred,
and it was all well covered by the media.
It's not all perfect, however.
There are some drawbacks to lap surgery.
Dexterity is a huge challenge.
If you try and visualize holding an 18 inch long steel tool,
which passes through this hole in the patient's skin,
the size of a dime or a five-pence piece,
the surgeon has to think about the angle,
the depth, the rotation of the tool relative
to the surgical site,
and the rotational movement will reverse
because they pass through this incision,
which is like a pivot point.
This is called the fulcrum effect
and it makes things quite unintuitive
hence we have the name Intuitive Surgical.
Interesting backstory to the name.
We'll come back to it.
So in laparoscopic surgery,
the surgeon might be manipulating
two of these long instruments by hand.
While an aid holds the endoscope,
that endoscope displays the surgical site
on a screen for the team to look at.
Also, the length of these tools amplify
any little hand tremors
that even the steadiest of hands might have.
So that's bad for precision.
And that's really a problem
when you're trying to stitch paper thin tissue
of an artery, for example.
The other thing to call out is this setup
is physically very taxing on a surgeon.
They've got their hands and their back
in an awkward, uncomfortable position
as they perform the procedure
and that might take hours to complete.
If you talk to surgeons who have experience doing this,
they'll tell you that after performing
two prostate tectomies, you need a physio.
It's really hard work physically
and there's evidence out there
which suggests that surgeons
who do a load of lap work over their career
are forced to retire earlier
because the toll this work takes on them,
which normally manifests as back pain.
The other drawback of laparoscopic surgery is visibility.
So that is inferior to open procedures
because the surgical site is not open,
you need to illuminate it
and use the camera to see what you're doing.
So there are a lot of benefits,
but there are some challenges as well.
Now, this is where robotic surgery
answers the timeline really mad.
Robotic surgery deals with a lot of the shortcomings
of laparoscopic techniques.
So the origins of this industry,
if we go to the 1980s,
the Stanford Research Institute
develops a surgical robot
and that caught the eye of DARPA,
the R&D Agency of the US Defense Department.
They were interested in the potential application
of a surgeon performing remote surgery on a soldier.
The idea was combine a robotic surgical system
in a field operating theater
with a skilled surgeon who sat tens or hundreds of miles away
driving the procedure
with a remote control and viewing system.
Now, unfortunately, this application never took off,
but the germ of the idea was there
and a young, intuitive surgical began commercializing it
in the mid 1990s.
The first prototype was called Lenny
after young Leonardo da Vinci.
And in 1998, the first model was released in Europe.
They IPO'd in 2000 and received FDA approval
for the Da Vinci system.
for prostate surgery the same year.
So that's the history.
- You painted a nice picture there.
If I'm to understand what is actually happening
with the DaVinci system,
is it actually using what you mentioned
with the laparoscopic tools,
but rather than putting a surgeon in place
to use those tools,
you're using a robotic arm.
Is that the right way to understand what's happening?
- Maybe the most useful thing to do
is to paint the picture of how one of these procedures works.
So to set the scene,
a DaVinci system in an operating room
consists of three main parts.
You've got a surgeon console,
which is where the surgeon sits,
a few feet away from the patient.
They're looking through a viewfinder
at what they're working on.
They've got controls for each hand
and controls for the feet,
which they use to drive the robotic arms,
control the instrument and perform the procedure.
What they're controlling is called the patient's side cart.
So this is the robot.
And I would encourage people to image search this
and it really brings it to life.
And that patient side cart,
that robot includes three or four robotic arms,
which holds surgical instruments
and an endoscope vision system over the patient
who's lying on the operating table.
Finally, there's another part called the vision cart
that includes a display for the other operating room staff
to view the procedure, to see what the surgeon sees.
And that vision cart can also house
some other technologies,
electro-esurgical tools and things like that.
So for the operation, a patient is under general anesthetic,
multiple keyhole incisions are made in the abdomen
through which the surgical instrumentation is placed.
And the surgeon is sat at their console,
controlling these instruments,
looking through the vision system
to see what's going on inside the patient's abdomen
as they perform the procedure.
- That makes sense.
And I'm thinking about these early days
for intuitive surgical in the digital world
and the tech world,
Facebook made, move fast and break things,
the popular motto there.
In the medical world,
that's not really a reasonable business plan.
You have very little margin for error
and particularly as you're testing these machines.
So can you talk about the early days
in terms of getting adoption,
whether there were major breakthroughs
or just the evolution of the DaVinci system?
And I'm curious how they won in this market,
whether it's just being a first mover
or anything else they were doing
with their robotics that differentiated them.
- So to be honest, how they opened up this market,
as you've already alluded to,
they had to come to market with something
that was pretty much a working, reliable solution.
There was a prototype we've talked about called Lenny,
but that was developed to the point where it was
suitably robust, reliable,
intuitive to use such that it could gain FDA clearance
for use as a surgical tool in the indication.
So initially in urology.
So back in the late '90s, early 2000s,
it was a similar value proposition to what we see today,
which is bringing all of the benefits of robotics surgery
and we'll go into exactly what those are in a second,
bringing all of those in a fully formed,
reliable form factor that they could actually
start to go to hospitals and surgeons with
and start to prove some value add
and start to improve over laparoscopic surgery
in a way that was suitably robust.
And as you've said, you can't be breaking things
and moving fast.
You need it to be reliable,
turning up doing the same thing every day
and to be entirely counted upon.
- Is this a market that requires regulatory approval?
Was that a step in this process?
- Yes, intuitive have been very good
at going around the world,
talking to different healthcare regulators
and getting what's known as an indication
in the United States for use of their system
for a specific procedure.
So you get clearance for a given procedure type,
in a given geography.
And so if you imagine the matrix
of all the different soft tissue surgical procedures
and all the different geographies
in which intuitive wants to play,
they've done the hard yards of liaising
with the regulator on each of those fronts
to make sure they get clearance.
I mentioned that in 2000, when the IPO,
that was the same year they got clearance
for neurological procedures on the initial divinci
and they've gone through other aspects of surgery
and they've had to do that each time
they introduce a new robotic system
and new generation latest iteration.
They've had to go through and do that for each surgical type
and then they do that in Japan, in Europe, in the UK
and so on and so forth.
- Yeah, I'm sure that starts to compound
in terms of the success that they've had
and working through those regulatory hurdles.
Obviously there's an approval process each time
but each time you have a success story,
I'm sure that's beneficial to future approvals.
We talked a little bit about this is mostly being used for
in terms of the soft tissue surgeries,
you particularly mentioned around the abdomen.
How big is the potential for robotic surgeries?
Just in terms of the total addressable market
which you referenced at the very beginning
and what this could possibly do in the future
what surgeries are just out of question
where robotics could never do them
and then maybe what is the runway
for future potential surgeries
that maybe they haven't quite yet addressed?
- Before we dive into the runway for growth,
I think it's probably important to detail some of the benefits
of robotic surgery because that's really what you're unlocking
when you're talking about unlocking these addressable markets.
So we talked about the history in the 1990s
and that took us through to the IPO in 2000.
But it's important to talk about the benefits
and the big fundamental advantage
that robotic surgery has over laparoscopic techniques,
dexterity and visibility.
The value proposition to patients, to surgeons,
to hospitals, to healthcare systems, payers, everyone
at a high level, those benefits
are still what you're offering today
and that was what the value prop was in the early 2000s.
So on the dexterity side, robotics is just so advantageous.
Each arm of the robot can be moved through three dimensions,
rotated, inserted, retracted.
Additionally, the instruments are listed
which means they have an additional pitch, role
and your movement inside the patient's body.
So that's a big difference with laparoscopic surgery
that risted aspects of the instrument
and the surgeon has a great deal of control
over the position and the angle of each instrument.
I should say the arms of the robots are calibrated
so that those rotations happen perfectly
through the incision point.
They mitigate that fulcrum effect,
which was the really unintuitive part of lap surgery
we mentioned earlier.
So that's why it's highly intuitive, again, hence the name.
Then there's the visibility aspect
and this is something that surgeons really, really appreciate
if you've talked to them.
The Da Vinci vision system includes dual cameras.
So the endoscopic's got two cameras on the end of it
and that means the procedure is viewed in 3D
which allows for depth perception
which is really, really important
when you're looking at the anatomy inside
of someone's abdomen and working on a procedure there.
That high resolution, so that lets the operative image
be magnified and this is why the surgeon sits
at their surgical console and views the image
through a 3D viewport at the console.
So they've got a different image for each eye
and that allows that 3D depth perception.
So compared to laparoscopic techniques,
robotics gives greater dexterity,
steadier, more accurate control of surgical instruments,
advanced visuals, better surgeon ergonomics.
Remember I said it's painful to stand over a surgical table
for hours with a robotic system
they're sitting at an ergonomically designed console
not holding tools over a patient.
And this is all in the pursuit
of better patient outcomes, specifically less variability
in the range of outcomes for patients,
more reliable surgical outcomes.
Remember with open surgery the actual procedure
on the internal organ is less often the short term risk
than the big hole you have cut in your abdominal wall.
And robotic surgery improves outcomes for patients
in terms of length of recovery time,
average length of stay in hospital,
the amount of blood lost,
the chances of needing intraoperative
or perioperative blood transfusions is way lower
with a robotic surgery procedure than an open one.
So compared to laparoscopic,
the likelihood of conversion as in mid procedure,
reverting to an open technique, the likelihood is lower,
the likelihood of readmission is lower.
So it's not just for the surgeon's benefit,
there's tons of patient benefits as well.
So that's what robotic surgery is really delivering
and we've talked already about the size of the market
and what the growth might look like.
I suppose one of the key questions in understanding
in chooses business is your question
of what's the potential growth runway
and from an analyst's perspective,
this is an amazing company to study.
They give you lots of disclosure
in terms of how many procedures are done,
what type of procedure,
what the installed base of robots is in different countries,
what type of robot is shipped in a given quarter
and so on and so forth.
The company are also very helpful
in highlighting academic studies relevant to robotic surgery
and that serves as a great jumping off point
into the question of growth and the growth runway ahead.
So if you look through the academic literature
very, very carefully at a whole range
of different surgical procedures,
you can start to get a sense of the propensity
for robotic penetration to pick up
in each of those different procedure types.
You can see where the benefits really show up
from a total cost of procedure perspective.
where they're more marginal. The speed at which penetration picks up is obviously hard to
know in advance, but it gives you a sense of what the true addressable market might be in five
years, 10 years, 15 years. And in my view, it's important that you look at that as well as the
headline figures of total number of procedures, total number of soft tissue procedures and so forth.
The work procedure by procedure really helps you understand how quickly penetration might move
up the adoption curve. So the benefit of understanding things like that, I mean,
understanding it to the degree that any non-medically trained investor can really understand these
things is you can disaggregate what's driving adoption forward. Is it say standardisation among
surgeons who trained on robots? Is it superior patient outcomes? Is it the superior experience for
the surgeon? Is it the brand? Now, just because you do all that work, it doesn't necessarily mean
that the future unfolds exactly as you've got it in the spreadsheet. And what's been really
interesting is growth in procedures where previously you thought it was unlikely there was going
to be a switch across to robotic surgery. If you talked a few years ago to some surgical department
heads, they would have probably told you gall bladder removal, which is technically called a colostistectomy,
is unlikely to ever switch over on mass to robotics. And the reason is that there was not an
incremental benefit relative to the incremental cost. It was a simple procedure that a less experienced
surgeon might be able to perform quite quickly. But we've seen from the results of intuitive that
this is an area that has been driving growth within general surgery. And that to me is an indication
of robotics becoming more standardised in many, many hospitals. Another thing that I'd probably
highlight in terms of what's driving growth and I've alluded to this is the dynamic of new surgeons
qualifying and older surgeons retiring and aging out of the population. Younger surgeons are way
more likely to have trained on a robotic system. They've got a higher propensity for doing some
or even all of their procedures on a robot. So that also helps growth. For those of you who had to
summarise all the things that are driving growth forward, you'd list the surgeon preference for
a robotic surgery, especially the narrower range of outcomes for the patient, more reliability,
as well as ergonomics. The evolution of surgeons towards younger cohorts are likely to be trained
in robotics. You've got an underlying growth in procedures, which coincides with rising
geriatric populations, improving cancer screening initiatives and other things. You've got
increasing applicability for robotics for new procedures as the evidence emerges of the benefits
in those sub-procedure types. And then another one that's quite interesting, health systems
in various places are looking towards outcomes-based approach to paying for surgery.
So pay for performance is something that's picking up in the United States. And this aligns
with the benefit of a total cost budgeting approach, which will come on to in a second.
Insuranceives lowered the financial barriers to adopting robotic surgery as well with flexible
financing options. That's another growth driver I'd point to. You hit on a lot there and I want to
start shifting towards the business model in a bit. But you were referencing some of the academic
papers that have come out and some of the studies done on robotic surgeries. And one of the interesting
things that I came across in my research was in the early 2010s, there was this negative thesis.
You had a stock that was extremely expensive. And what seemed to be the case was that the data
didn't necessarily point towards robotic surgeries having much difference in terms of outcome.
But it was mostly that surgeons like to use it and that it was almost a marketing tool
for some of the centers that they could market to potential patients. So it was very much driven
by the demand more so based on evidence that it was better. Can you talk about how that's
evolved over time? That was very much a place in time 10 plus years ago. But just in terms of what
you were referencing there in the growth, you still mentioned surgeon's interest in using it,
patient's desire to have robotics work with it, which are two very important things and
major drivers. But how much of it is actually backed by data? That's a really good perspective
to maybe talk about the trade-offs and the perceived trade-offs of robotic surgery. So I mentioned
some of the benefits which you could broadly summarise as narrower range of outcomes,
more reliable outcomes for patients. But there are trade-offs and the big one that's often cited
is cost. And the upfront price of a robotic system might be a million and a half dollars,
which is analysed over its useful life six or seven years, say two or three hundred
procedures per year. Plus you've got to pay for instrumentation which, on average,
$1800 per procedure. Now you might say those figures sound excessively expensive,
and that's not an unreasonable thing to say. But the pushback is it's not about cost,
it's about value. Now that sounds a little cliché, but with robotic surgery it's really
important to consider a more holistic budgeting approach. And if one considers direct
and indirect cost of a procedure, then robotic surgery starts to look quite good value despite
the high headline costs. So lots of academic studies have actually done a terrific job of analysing
the holistic cost for different procedure types. And this talks to the demand beyond just surgeons
and the brand wanting to use these robotic systems. So if you look at the prostate
tech to me, which is the single procedure where robotic penetration is the highest,
the cost of surgical equipment for a robotic procedure is four times higher than the equipment
needed for an open procedure, and twice that of a laparoscopic procedure. But the cost of the
subsequent stay in hospital is lower. If you go with the robotic option, the cost of recurrence
treatment is lower. The risk of distant metastasis and associated treatment is lower. The cost of
palliative care is lower. The all-in cost once you account for the related indirect cost of a
treatment is lower for the robotic option while carrying the other benefits we talked about earlier.
Another way you can frame this point I suppose is to point out that direct supplies are typically
the smallest component of a procedure cost. A long way behind wages and other indirect costs
once you account for the cost of the OR, depreciation of the building, other equipment.
These benefits and relative costs obviously vary from one procedure to another. And that's
another important consideration when you think about that matrix of the growth runway across
different procedure types and geographies. The other trade off I'd mention is being transparent
on it is procedure time. So several procedures actually take longer on a robot than they do
laparoscopically. And this is because a significant amount of time when using a robot is the
docking and undocking process. So that needs to be taken account into the cost measure as well,
the cost of the OR time and staff. But perhaps the surgeon isn't needed for the whole time.
The surgeon can join for the procedure once the instrumentation is in place and the robot is
docked. But it's a consideration as well. And this goes to another question you are in terms
of areas where robotics is less likely to be used. The extra undocking time also carries another
risk. If something goes wrong, it's slow to get the robot undocked and out of the way. And for
surgeons to get to work on whatever life-saving intervention they need to do like stopping
bleeding. And this is part of the reason why robotics is not widely used in most cardiothoracic
surgery. It's too dangerous to have this undocking slowing you down. It's something goes wrong
with the lungs or the heart mid operation. Whereas if you puncture a hole in the bladder,
the patient isn't going to die right away. They can undock the robot and then set about fixing
the mistake. So this academic work and documenting the value ad across different surgical types and
the cost and benefit is what hospitals look for and surgeons look for when they're thinking about
adopting robotics is not just the allure of the brand and the latest greatest technology.
Very interesting to hear about some of those trade-offs and not even things that I would
consider just in terms of the docking and the undocking in the time to set up. I did want to
touch on a point about market size and whether there's any evidence that it actually expands the
market for procedures. I could potentially make the case that I might be more willing to do a
procedure if there was a surgical robot doing the work rather than just certainly being cut fully
open and potentially relative to laparoscopic. But is there any data or evidence that it's actually
expanding the market of procedures done because of the interest in using it?
I don't think it's fair to assume that's the central case because many of the procedures where
this is being done in urology and gynecology, for example, are not benign procedures and so these
are not something where the patient has the luxury of waiting and choosing between surgery or not.
Normally these more serious requirements and therefore there's going to be a surgical procedure
undertaken and there's a greater comfort involved in what you get with the robot and the narrower
range of outcomes and the steadier greater control over the procedure which the surgeon gets.
I don't think it's quite fair to say it's expanding the market from that perspective.
I appreciate when I guess we'll push back on something that might otherwise be a bullish or
positive thesis. So I appreciate the pushback on that point. We can transition a bit into the
DaVinci system and how that's evolved. I think you referenced there just in terms of the upfront
cost and the useful life which you mentioned six years. But maybe
Maybe we just start with the DaVinci system and the evolution over the time frame since
being introduced.
Is this something where we have DaVinci 1, DaVinci 2?
How do updates come into play?
What do those look like?
Maybe just a little bit about the DaVinci system itself?
Sure.
So since the 1999, 2000 time intuitive have introduced four generations.
So exactly as you say, you've got DaVinci 1, DaVinci 2.
And actually earlier this year, they announced their fifth generation has been submitted to
the FDA.
And the new versions, the new systems, they bring new features, they bring improvements
on all the things we've already discussed.
Division systems get better, the degrees of motion get improved, they integrated operating
table motion and so on.
There were also some feature sets were introduced, which I think are quite important junctures
in the story of DaVinci and its competitive landscape, I suppose.
Now, if you were to think the emerging competitive threat to the incumbent surgical tools market,
that intuitive grew, intuitive was growing with a botic surgery and it was taking share
from laparoscopic, taking share from open procedures.
If you were to think all of that growth was unknown or unknowable to the incumbents that
were being somewhat disrupted, then you might be surprised to hear this.
Up until 2014, there was no stapling instrumentation from intuitive.
So surgical staplings, a common method for closing up work that's been done in the operation
in the procedure and prior to the launch of stapling tools by intuitive, surgeons had
been standing up from their DaVinci console, scrubbing into the procedure and then carry
out the stapling using a tool from another provider.
There was a similar story for energy systems, so you have tools such as vessel sealers
and intuitive first introduced those just over 10 years ago, prior to that, like with
stapling surgeons, we're getting up from the console scrubbing in and using a third
party electro surgical tool to coagulate and cart or seal tissue.
So intuitive didn't have the whole procedure covered in the early days.
Its systems were being used in hybrid with other surgical tool providers and in my mind,
that was a bit of a missed opportunity by the competitors.
They should have seen this growth in robotic surgery, seen that surgeons were embracing
it as the future and, of course, seized on the fact that intuitive at the time did
not have all of the basis covered.
They only provided the simpler tools and were being supplemented by third party staplers
and vessel sealers and energy systems.
But intuitive worked left as the sole player of robotics through most of the 2010s and during
that time they developed, launched stapling and energy systems, plus they demonstrated
the effectiveness and the reliability of those tools.
If you're a surgeon, you don't use a stapler unless you trust it 100%.
You don't want to be having a re-admission opening a patient back up to fix a burst staple
or a failed staple.
And an unproven intuitive stapling system took a few years to be accepted.
Today those stapling and energy tools, which were new introductions 10 years ago, are now
clusters advanced instruments and these contributors more than a billion dollars of revenue in 2023.
So a meaningful contributor from these later developments, the advanced instruments.
And then if you think about upgrades through the generations of the Da Vinci system, replacement
and upgrade cycles, these are actually arguably of greater importance to the fundamentals
of the business trajectory a few years ago.
So previously a new robot would be announced.
They'd go from generation three to four.
This would spur an upgrade cycle, supporting capital placements as in robotic placements.
But intuitive have de-risked the product cycle nature of their business model in two important
ways.
One is they've started to offer leasing and two, they've offered upgrade clauses in the agreements
they've got with hospitals.
And this de-risks the potential for volatility in their own business as hospital placements
should now be smoother and it de-risks for the hospital, the decision of having to worry
about buying a robot just before a new generation gets announced and your new purchase becomes
obsolete.
So that's the story of introductions over the last two decades.
The only other thing I would mention on new offerings is in addition to the Da Vinci ecosystem,
more recently intuitive have developed and unveiled a second product group called Ion.
And this is what's called an endoluminal system, which at the moment is used for minimally
invasive biopsies in the lung or bronchoscopies.
Most people are probably familiar with this, but why do we carry out bronchoscopies?
Well, lung cancers, the leading cause of cancer death, unfortunately, and 25% of all cancer
deaths are represented by lung cancer.
So it's a big problem and the survival rate on lung cancer is low, partly because of
late stage diagnosis and survival rates can improve a lot with early diagnosis and treatment.
So every year millions of people have chest radiographs and CT scans and sometimes nodules
are detected in the lungs in those scans.
The problem is most of the time those nodules are in hard to reach peripheral parts of
the lungs and traditional bronchoscopy techniques give you pretty limited access to those areas.
And that's often where lung cancer is first developed.
So pulmonologists who work in this field have a dilemma on their hands.
They want to detect the cancer as early as possible.
And that means taking biopsies of smaller, earlier nodules, but there's a greater probability
of a small nodule being benign, so you need to balance the probabilistic safety.
That hesitant of checking every single nodule with a traditional, trans thoracic needle biopsy,
if that risks collapsing along, especially when early nodules are more likely to be benign.
So there's a huge unmet need for an easy, safe, less invasive bronchoscopy that can
navigate, you could call it torturous anatomy of the lung and accurately biopsy these small
lesions.
And that's what the ion system does.
It's a super thin, three and a half millimeter diameter, flexible, robotic bronchoscope.
And that can be used to navigate the lungs and find these areas in question for biopsy.
Interestingly, in terms of share, this market for flexible bronchoscopies with J and J,
with their monarch offering.
So the competitive position is a little less dominant than in the main business.
But these flexible bronchoscopy tools are growing very, very quickly from next to nothing
in 2019, insuritives ion systems did 54,000 procedures last year, and the installed basis
grown 10X in three years.
So that's an example of another product group, another innovation, which is still minimally
invasive, still robotic surgery, answering a significant unmet need, and talks to the
innovation going on at insuritif.
Yeah.
The possibilities are just fascinating in terms of non-invasive surgeries and what it can
potentially do when you mix that with advanced innovation and monitoring and detection as
well.
You hit on a very interesting point on the revenue model.
I was very curious to get into this when you presumably have a system that you're updating
to your point once every six years or so.
That can create some type of volatility, cyclicality, not much visibility.
When you mentioned transitioning a bit towards leasing the equipment and offering those
upgrades, I imagine there's some type of maintenance/service line here.
But can you break down just the revenue buckets, however you or the company would break them
down?
Sure.
So maybe just to remind people of the scope in terms of robots and then how that flows
through to revenue.
So last year, insuritiv place just shy of 1,400 of these systems, the DaVinci systems.
And that generated 1.6 billion dollars of revenue.
Once you strip out some moving parts, the system ASP is 1.4 to 1.5 million dollars and
there's currently an installed base of eight and a half thousand of these robots globally.
But the larger part of the business from a revenue perspective is the sale of instruments,
accessories, and these sales are the ones tied to procedure volumes.
I've mentioned, in 2023, there were 2.3 million procedures performed on DaVinci and the instruments
shipped to enable these procedures generated over 4 billion dollars of revenue.
So the simple math tells you that insuritiv are earning about 1,900 dollars of instrument
revenue per procedure.
And then exactly to your point, there's additionally some servicing revenue attached to the systems
and the install base, which generated around a billion dollars last year.
So the revenue breakdown is 7 billion dollars total last year, 60% of which is instruments,
65% of which is system revenue, and the remainder is servicing.
One thing to say, which you hit on exactly correctly about the systems revenue, the robots
is unleashing, which we've touched on, intuitive offer the ability for the hospitals to de-risk
that capital budgeting decision by offering the robotic system on a lease.
And what that means from a financial model perspective is the robots shipped to the hospital,
but it sits on intuitive balance sheet at cost as a line of PP&E, and that it's depreciated
over its useful life, meanwhile the lease payments, operating lease payments, get
booked as revenue into the accounts.
Now those lease payments might be fixed.
mixed on a per month per quarter basis,
all they might be usage based.
And then with the latter, the payments are really tied
to procedure volumes, but then the hospital
would be contractually locked into some minimal usage level.
And so the risk of idle robots
isn't entirely born by intuitive.
- When you think about the drivers
and maybe the mix shifts,
is it getting more of these systems into the market?
Do you expect that percentage to shift in terms of
what that service line represents
as a percentage of total revenue?
How do you think about the drivers there?
You can make the case that it's either more procedures done,
which would drive that service revenue
to the extent that it's usage based,
or that it's simply more penetration,
more selling into the market.
- I think the way to think about
how the revenue model unfolds over time
is that it's all led by procedures.
And so as intuitive demonstrate the efficacy
of robotic surgery and they bring incremental innovation
and bring new features and tools and so on,
then you're gonna see more and more procedures done
on the venture systems.
And that flows through to an install base over time,
which has grown relatively monotonically as well,
albeit the install base has grown slower
than the procedure number.
The balancing part of that equation
is utilization as grown.
So the number of procedures per year has gone up.
Suppose you could say that the service revenue per procedure
has gone down, but intuitive would be very happy with that.
They know that it's all about unlocking
the maximum amount of value from a given robotic system
and the associated service.
And that means driving procedure penetration.
So it waterfalls down from procedure volume,
install base volume, the associated revenue
of systems and services.
You've referenced a bit about depreciation schedule,
useful life.
In reality, are these systems used beyond six years?
Is there a secondary market for them
if you were to have some type of downturn in the economy?
Could you see some of the customers
maybe sweating the assets a bit more,
extending the life of those systems?
How much does that play a role?
- It plays a role to some degree,
although once a hospital or a customer starts
really getting decent utilization out of a robot,
then there are so many other costs associated
with a given procedure that the depreciation
of a single procedure of that robotic system
starts to be smaller.
And this is again a point about the brilliant disclosure
that intuitive give you.
You do get given the number of trading systems.
So while they ship new systems,
they also take trade-ins from the market.
So there might be older robots, the previous generation.
They might be retired or if they've still got some useful life
and they need some upgrades and maintenance.
They might actually be shipped out at low ASP
to other parts of the world,
which may be can't support the latest greatest
most expensive model,
but maybe have an appetite for still the benefits
that you get at a lower ASP.
So you get some trade-in
and maybe in an era of economic weakness,
you get some delayed purchase of the new system,
but certainly in certain parts of the world,
the US being the biggest market for intuitive.
Surgery and these procedures tends to be margin-accretive.
And you don't need to necessarily think
about over-squeezing your asset
or running it longer than you ideally should
because this revenue attached to the procedure.
And as we've said,
big portion of the costs of the other parts,
the labor, the building,
and the instruments and accessories as well.
- And for intuitive themselves,
thinking about the cost line, the investment, R&D,
CapEx, whatever it might be, how much variances there
from year to year in the margin profile of that business,
and then the ultimate free cash flow of the business as well.
- So the headline is that the business earns around
about 70% gross margin,
which is actually quite similar
across product revenue and service revenue.
The product side sometimes dips down a little bit
when they're scaling up a new offering.
So I, on at the moment, that end-illuminal system
I taught through, that's currently not running
at a large manufacturing capacity or at scale,
but it's growing quickly.
So that can pull down the gross margin a little
in the short term as that scales
into its manufacturing footprint.
But generally, high 60s is where the gap gross margin sits
and a bit higher for a adjusted gross margin.
I should also point out that the leasing set up
that we've mentioned, the associated revenue
and depreciation expense of the robot that's on a lease
drops through at the same gross margin as an outright sale.
If you move down the P&L to operating expenses,
intuitive spends in the region of 14% of sales on R&D
and then 26, 27% of sales on SG&A.
That's on a gap basis.
So you're looking at a high 20s, low 30s gap operating margin
and depending on how you like accounting for stock-based comp,
the adjusted operating margin is 7, 8, 9, percentage points higher.
But yeah, exactly to your point, what does that mean for cash?
Well, historically, this was simply a simple sales business,
sell the robots to the hospitals,
then sell instruments and accessories
and you get pretty predictable attach rate on services.
And the market used to actually focus on capital spending
to your points earlier, as this drove incremental installs.
Now, the introduction of leasing breaks that link somewhat
between hospital capex cycles and sales momentum of division.
That gives greater forecastability,
but there is a trade-off, which is cash conversion of leasing.
So the accounting treatment I mentioned,
the system being capitalized up front and sitting on the balance sheet
while you don't get the revenue until it flows in over time,
that acts as a drag on cash conversion.
But not a detrimental one.
And in my view, it improves the relationship
and the stickiness with the hospitals
and the overall business health.
So even once you've taken that into account,
a fairly limited amount of capex albeit is slightly higher
at the moment as they build that manufacturing facilities,
this business still produces a ton of cash
even with that marginal drag from leasing.
Very interesting.
And when you think about the R&D expense as well as capex,
how much of that is going into new systems like Ion
versus maintaining the existing business
is a lot of cash being spent on more innovation.
Know it's hard to separate maintenance a little bit
when DaVinci is consistently being updated.
But I am curious about that.
Yeah, it's definitely hard to pass out
because you don't get given that broken out.
But the company have told the market
that not only have they been working
on the fifth generation for many years,
which they've now announced this year has been submitted
to the FDA, but they've also had the sixth generation
in development as well as the Ion system.
There's also a single port version of DaVinci,
which I didn't go into detail on,
but that involves all the instrumentation
through a single incision in the abdominal wall.
So they've been developing new systems like that
relatively regularly and updating things,
but maybe somewhere I would touch on where that R&D engine
has really been put to work, especially in recent years.
And that's digital capabilities.
So that's been much more of a focus of their development efforts
and they've shipped and are shipping
a more comprehensive set of digital tools,
if you like, in the last few years.
And the premise is that they've been capturing
a ton of high-quality data relating
to all the procedures done on their systems,
which are all high-tech cloud-connected systems, by the way.
And you can, I suppose, bucket these tools into three camps.
So these tools are aiding pre-op planning,
interoperative guidance, and then post-op analytics.
So if you think about the pre-op side,
surgeons, consultants, they can use 3D models
of a patient's anatomy taken from a diagnostics tool,
and then they can use that to plan the operation.
So you end up with a kind of augmented reality
for the procedure.
You also have a simulation software,
so surgeons can work on their robotic surgery skills
in a simulated environment.
So you've got these different digital tools pre-op.
In terms of interoperative guidance,
as well as the 3D model, the augmented reality being there,
from that planning stage, there's also
something called intuitive telepresent,
which is they describe it as a hippocompliant face time.
So you can have proctoring of the procedure live,
but digitally, and then finally post-op tools.
Some of these are actually still in prototype,
but these tools would let the surgeon or the hospital
or the head of the surgical department
maybe do analysis on a procedure after it's been concluded.
So there's a tool called Case Insights,
which compares your procedure to a huge sample
of similar procedures, and shows the surgeon
where they did really well, where they could have done better.
There's also a portal for the hospitals
to monitor their usage of instruments, usage
of the robotic systems, resource planning, and so on.
So it all makes their robotics department
within the hospital more efficient.
So that's somewhere where they've been focusing
their efforts in recent years.
Those digital tools have been taking an increasing share
of R&D spend.
- When you start to think about competition,
I think you alluded to with Ion,
there's more of a natural competitor with J&J in that market.
Maybe we focus on the DaVinci system itself,
competition in that market.
It seems like what you reference,
they have about 10% of the share in that market today.
Is that something that you'd like to talk about?
that you expect to continue to grow in terms of them continuing to gain market share,
and are there any major competitive threats in terms of companies putting major investments
for a competitive product that exists today?
They've got essentially 100% market share in Robotic Surgery, but the market is maybe
only 10% penetrated.
And at this point, intuitive have grown quite a big profitable business, and so it is attracting
some competition.
For context, there was a legitimate competitor in the early days called computer motion.
Back in the 1990s, it was founded specifically to develop surgical robots, borrowing NASA
technology, and they did a really good job with their Zeus surgical robotic system, and in
fact, they sued intuitive in 1998 for patent infringement.
After five years of litigation, the two companies merged under the name intuitive surgical.
And for much of the time since then, intuitive have been pushing forward this market alone.
The competitors that are entering the market today can be broadly grouped into two buckets.
On one hand, you've got large legacy surgical tools businesses looking to defend their business
as the world moves increasingly towards robotics.
And then on the other hand, you've got smaller startups seeking the promised land occupied
by intuitive, a big business, high margins, high returns on capital, and so forth.
On the first group, there's almost something of a syllogism where one of the big diversified
medical device businesses like metronik, for example, says we're in surgical tools.
Robotic surgeries are bright spot in surgical tools.
We should do robotic surgery.
And I'm not sure that's the right mindset as a starting point to really make something
innovative that surgeons really want to use, metronik cannot particularly focused on robotic
surgery.
It's one product line of many within one of their four divisions.
Now they have a product in market, and I'm sure they will get some traction, but by definition,
it doesn't get the same level of focus up and down the organization is what intuitive
gives to their robotic surgery business.
So maybe it's worth asking how robust is intuitive's competitive position.
Well, their technology leaders, they have learnings from 25 years of research, and billions
of dollars of cumulative R&D spend.
They've now announced their fifth generation robot, and the latest versions encapsulate
a ton of electromechanical engineering, know-how, software development, and so on.
Meanwhile, there would be competitors who are only coming to the market now or in the
last couple of years.
So you could argue they've got some catching up to do.
The second thing I'd point to is FDA approvals, to go to market with a level of scale that's
attractive enough to be considered by hospitals and healthcare systems, your robotic system
it needs to have sufficient regulatory clearances.
Intuitive have done the hard yards of getting clearances for different procedure types in
different countries.
It's a slow process to go through and build that up.
Finally, I'd point to intuitive having nurtured their ecosystem quite deliberately over the
last 20 years.
They've got a highly engaged install base at this point of surgeons, of hospitals, heads
of surgical departments, academic groups.
Each part of the value chain is bought into DaVinci, and hospitals are very hesitant to
change their surgical robotics provider.
Surgeons don't want to learn a new system, administrators have built resourcing workflows
and budgeting processes around the DaVinci.
So intuitive have offered leasing, which lowers the financial burden of making the decision
on buying robot.
The length of time they've been in the market means there exists a vast amount of data
on the 14 million DaVinci procedures that have been done today and that data feeds into developing
digital tools, it feeds into R&D and it feeds into clinical evidence.
I mean, there have been 38,000 peer reviewed academic articles published today relevant
to robotic surgery.
They've been 3,000 in the last year alone and the vast majority of these are done independent
of intuitive.
Surgeons don't adopt these robots purely on the basis of better ergonomics and a compelling
sales pitch from the salesperson, they want to know that the benefits that we've talked
about play out in reality and they want to see clinical evidence of that.
Surgeons can look at the independent studies, they can look at meta-analyses, they can
engage the pros and cons of adopting robotics into their scenarios and the body of evidence
is a huge barrier to entry.
So a new system comes to market, there's nowhere doctors simply assumes what happened in
a DaVinci system happens in the new one and you get this quite virtuous cycle.
R&D investments get a workable system that gets approved by the FDA, you ship that to
a wide enough install base that are engaged using the system, the procedures being done
generate a ton of data, that feeds the academic work, it proves out the efficacy of your system
and it feeds back into R&D.
I think in truth we've been quite careful about improving their relationship with all
of these aspects, they've been there for a long time, they're focused on robotic surgery
and they live and die by the success of that business alone.
So I feel quite comfortable with the competitive position but it's fair to say there are people
answering the market and I'm sure they'll gain some traction.
This is a large fast grow market, there's lots of space to innovate and more than one
player can succeed here.
On the geographical opportunity, what does their market exposure look like in the US relative
to the international opportunity and is that a key area for growth expanding abroad versus
further expanding in the US?
It definitely is an area for growth, it's a challenging thing to analyze, the data that
comes from the United States, health systems and the academic literature is really great
at painting a picture of the potential growth runway there and it's obviously more challenging
to do it across a couple of hundred other countries where the disclosure is more patchy.
But there's definitely a growth runway there and some of the things that insuritif has
done in recent years have obviously lowered the barriers to adoption.
So extending the life of the instruments, so it reduces the per procedure costs, offering
leasing the potential for traded in systems to be then shipped out at a lower ASP.
So there are a number of things that insuritif are doing to broaden out that international
market.
Obviously, the international market is not a monolith and some countries spend a lot on
healthcare and recognise the benefits of total cost budgeting, thinking about the value
versus just the headline cost and then in other countries the healthcare systems are more
stretched financially and therefore adoption of something that's perceived to be expensive
is more challenging.
So there's definitely a long runway there and the fact that insuritif's business is still
two thirds US, one third XUS, while obviously the population and the number of procedures
that are being done XUS, even in the richer countries in the world with well-developed
healthcare systems, if you just look at the penetration in OECD countries, there's clearly
a long runway there and I think insuritif do a terrific job of carefully leasing with
local regulators, local surgical associations, local healthcare groups in different countries
around the world, extolling the virtues of what they do and then working with those
different systems to see what they can bring to the market in terms of clearances and demonstrable
efficacy and so on and so forth, they're very very disciplined but going through those
different styles from a procedure country perspective.
I think we've done a very good job laying out the continued opportunity for growth here.
As you think about the risks for this business, we touched a little bit, Stan competitive threats
or how much we want to view competition as a threat, what else would you point to in terms
of risks for this business?
If you characterize robotic surgery as disrupting other forms of surgery, it's fair to say the
flow of disruption is not one way and in fact, insuritif have been actually on the receiving
end of some disruption in one small corner of their business and this has been actually
quite a focus for people who follow intuitive over the last few quarters and that's GLP's
being the weight loss disruptor in bariatric surgery.
So last year, 2023, we heard a lot about GLP1s and numerous studies read out as a result
lots of companies felt the impact of the market anticipating disruption to their business model.
Some of this was obviously very direct.
The direct diabetes businesses felt it probably the most severely but even snacks businesses
obviously people anticipating disruption there.
Also, some more indirect impacts felt from the advent of GLP1s being more widely adopted.
Intuitive impact is actually quite direct or be it small in the overall mix of their
business and robotic systems are used for bariatric procedures which use to treat morbid obesity
and therefore the secondary effects such as diabetes.
GLP1 type drugs obviously offer a substitution here if you're morbidly obese if you're at
risk with diabetes or suffering from diabetes there's a substitution and understandably patients
are deferring surgery while they assess the options of GLPs.
Surgery is seen as a more drastic option and so people are taking pause while they assess
the new options have been brought to the table more recently.
There's two things I'd probably call out to consider here, one the deferral might occur
for a year or two while the patient tries GLP1s but we know that longer term levels of adherence
to these drugs and not widely.
know we don't have super high confidence bars as to the level of adherence across different
patient populations here. So there is at least some likelihood that bariatric surgery might
down the lines supplement GLP ones as an aid to longer term weight loss and diabetic health.
Two, maybe something that's not immediately obvious, but some morbidly obese patients are
considered too high risk to operate on for other non-bariatric procedures. So if GLP ones actually
allow weight loss, they potentially expand the addressable market for surgery. People that were
previously not eligible and their doctor's deemed them too high risk for surgery and that potentially
expands the market again for robotic surgery. So while intuitive or fairly sanguine about the
impacts of GLP ones on their business, one could argue that this is the canary in the cold mind
for surgery or maybe that's too extreme a metaphor, but one generally could get more worried if
you thought that pharmacological healthcare improvements over time would use the need for surgery.
As we improved biologic drugs, personalized medicine, improved diagnostics,
bring down cost of gene sequencing, all these things where there's been tons of innovation. Do
those developments erode the need for surgery? If broadly surgery is typically a more drastic
solution than farmer based healthcare, then advances in all of those things are certainly
something to monitor. But overall, I think the way intuitive manage this business very carefully,
very deliberately, no rash decisions means they're pretty well set to navigate whatever it is
that other healthcare innovations throw up, but it's an interesting monster monitor.
If you weren't mentioning ozemic as one of the risks I was going to ask you about it, so I'm glad
that you jumped on that for me. As we finish out these conversations, we always try to pull out
lessons that we can look out from a broader level and maybe apply them across your investing
framework. What lesson stands out to you from intuitive surgical?
I think the biggest lesson for me is the benefit of focus, and it goes back to that competition
points as well. I think a preconceived notion that in healthcare, M&A often makes sense,
because of course, if you can broaden out your product offering which you sell into an existing
customer set, then you get huge cost energies. This has led to quite large, quite diversified
businesses and the incremental products you acquire don't require any additional sales force,
so they accrete to incremental margins. If you look at the landscape of public companies,
there are some successful operators obviously using that playbook, but there are also some cases
where innovation is maybe lacking in lots of parts of the portfolio, not to the detriment of the
whole business, but you get pockets where innovation is lacking. A lack of focus is something to do
with it in my view. There are huge returns to focus, and this I think especially is true when
you're selling to clinicians. They're professionals who value genuine innovation, they value reliability,
they value improved clinical outcomes, much more so than the benefit of dealing with less
providers. So maybe in some pockets of, I don't know, life sciences or other medical supplies,
where the procurement decision is being made by someone closer to the budgeting process,
the diversified model makes sense. But for intuitive, they just do surgical robots driven by,
they've got this vision that minimally invasive surgery can deliver better outcomes for their
stakeholders. And by focusing singularly on this aim, they've developed the robotic surgery
market basically out of scratch. They've made a huge success of it over time.
Yeah, it's an excellent point. I was going to remark something about them competing with giants
in this world, but at 140 billion dollar market cap, I think it's fair to consider them
to be one of those giants. So a very excellent point in terms of the value of focus and
when you can truly create a market, the opportunity is endless. And this has been an excellent
conversation, Joe. I appreciate you not only introducing us to intuitive surgical, but also
into the broader world of robotics in the surgical market. So thank you very much for joining us.
Thanks for having me on that.
To find more episodes of breakdowns ranging from Costco to Visa to Moderna,
or to sign up for our weekly summary, check out joinkolasers.com. That's join, collosss.com.
Podcast Summary
Key Points:
Intuitive Surgical dominates the robotic surgery market with 100% share in robotic procedures, primarily in abdominal soft tissue surgeries.
The DaVinci system offers superior dexterity, 3D visualization, and surgeon ergonomics, significantly improving patient outcomes and reducing recovery times.
Early adoption was driven by reliable, FDA-approved systems, with Intuitive overcoming skepticism through clinical evidence and long-term data validation.
Revenue comes from robots, surgical instruments (earning ~$1,900 per procedure), and services, with instrument sales being the largest segment.
Leasing and upgrade models reduce capital risk for hospitals, stabilizing revenue and increasing long-term adoption.
The company has expanded into new areas like the Ion system for lung biopsies, addressing unmet medical needs with minimal-invasive robotics.
Strong R&D focus is on digital tools for pre-op planning, intraoperative guidance, and post-op analytics, enhancing surgeon performance and data-driven outcomes.
Competitive barriers include deep ecosystem integration, extensive regulatory approvals, and a robust body of independent clinical evidence.
Summary:
Intuitive Surgical is the market leader in robotic surgery, with a dominant 100% share in robotic procedures for abdominal soft tissue surgeries. The DaVinci system revolutionized surgical outcomes by offering superior dexterity, 3D visualization, and better surgeon ergonomics, leading to faster recovery times, fewer complications, and reduced hospital stays. Despite high upfront costs, robotic surgery demonstrates strong value when evaluated holistically—accounting for reduced readmissions, lower recurrence risks, and lower long-term care costs.
Intuitive’s success stems from decades of innovation, regulatory compliance, and deep ecosystem integration with surgeons, hospitals, and academic institutions. The company has expanded beyond core urology and gynecology into new areas like the Ion system for lung biopsies, where it has achieved rapid growth. Revenue is driven by instruments (the largest component), robot sales, and services, with leasing and upgrade options reducing financial risk for hospitals.
Digital tools now play a major role in pre-op planning, real-time guidance, and post-op analytics, enhancing surgical precision and training. While competition exists from legacy medical device firms and startups, Intuitive’s competitive position is reinforced by extensive clinical evidence, a loyal installed base, and a virtuous cycle of data collection and innovation. The business remains highly profitable, with strong margins and consistent cash flow, supported by a growing global footprint and increasing adoption in emerging markets.
FAQs
Intuitive Surgical's main product is the DaVinci robotic system, which performs minimally invasive surgeries. The surgeon controls the robot from a console, using robotic arms to manipulate surgical instruments through small incisions, providing greater dexterity and precision than traditional laparoscopic surgery.
Robotic surgery offers superior dexterity, 3D visualization, better surgeon ergonomics, and more precise control. It results in fewer complications, shorter hospital stays, less blood loss, and lower rates of readmission compared to open or laparoscopic surgery.
Intuitive has maintained a near 100% market share in robotic surgery through extensive FDA approvals, long-term clinical validation, a strong surgeon and hospital ecosystem, and a focus on reliability and value. Their deep product integration—including stapling and energy tools—reduced reliance on third-party devices.
Revenue comes from three main sources: system sales (robots), instrument and accessory sales tied to procedure volume, and servicing revenue. Instruments generate the majority of revenue, with over $4 billion earned in 2023 from 2.3 million procedures.
While robotic systems have high upfront costs, the total cost of care—including hospital stay, recurrence treatment, and post-op care—is often lower. Academic studies show that robotic procedures reduce overall costs and improve outcomes, which supports broader adoption despite initial expense.
Intuitive has launched the Ion system, a flexible robotic bronchoscope used for minimally invasive lung biopsies. This addresses a significant unmet medical need, with procedures growing rapidly and installed base expanding 10x in three years.
Chat with AI
Loading...
Pro features
Go deeper with this episode
Unlock creator-grade tools that turn any transcript into show notes and subtitle files.